Bullous pemphigoid associated with nintedanib
| Autor: | Amelia M. Hasson, Jay C. Vary, Gregory Cheeney, Lawrence A. Ho |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
bullous pemphigoid
medicine.drug_class BP bullous pemphigoid Case Report Dermatology Fibroblast growth factor Tyrosine-kinase inhibitor 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound Idiopathic pulmonary fibrosis tyrosine kinase inhibitor 0302 clinical medicine nintedanib medicine IPF idiopathic pulmonary fibrosis Adverse effect Lung business.industry acneiform-like eruption medicine.disease Vascular endothelial growth factor medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Cancer research Nintedanib Bullous pemphigoid business |
| Zdroj: | JAAD Case Reports |
| ISSN: | 2352-5126 |
| Popis: | Bullous pemphigoid (BP) is a subepidermal autoimmune blistering skin condition that is sometimes induced by numerous medicines.1 We report the case of a patient who developed BP shortly after starting nintedanib, a tyrosine kinase inhibitor approved for treatment of idiopathic pulmonary fibrosis (IPF). IPF is a progressive scarring disorder of the lung associated with significant mortality and morbidity. Although there is no cure for IPF, 2 medications appear to slow disease progression: nintedanib and pirfenidone.2 Nintedanib works as a tyrosine kinase inhibitor, targeting numerous receptors, including vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor.3 The most common adverse effects from nintedanib are gastrointestinal events, mainly diarrhea.3, 4 Reports of adverse dermatologic effects from nintedanib are less common, and there are no reports, to our knowledge, of nintedanib-induced BP. Accordingly, the purpose of this case report is to shed light on BP as a possible adverse reaction to nintedanib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|